Literature DB >> 7088232

Spectrum of rapidly progressive (crescentic) glomerulonephritis in northern India.

S C Dash, K K Malhotra, R K Sharma, P Kumar, R N Srivastava, U N Bhuyan.   

Abstract

36 consecutive patients whose biopsies showed significant extracapillary proliferation in the face of rapidly declining renal function were reviewed between 1967 and 1979. About 30% of the patients belonged to the pediatric age group with a male:female ratio of 2.5:1. Oliguria/anuria, hematuria, and progressive renal insufficiency were present in all cases. There was evidence of 9 cases being poststreptococcal, 2 SLE, 1 Henoch-Schönlein purpura, 2 possibly viral and 1 staphylococcal. Histologically, 29 cases had more than 60% crescents, 5 between 50 and 60% and 2 cases a little less than 50%. 28 cases were fatal in less than 10 months. 2 were lost of follow-up. 6 survivors with reversal of renal functions had 3 common factors to note, namely an antecedent disease, less crescents both in number and size, accompanied by fewer interstitial changes and early treatment. Rebiopsy in 2 survivors showed regression of histologic severity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7088232     DOI: 10.1159/000182431

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  2 in total

Review 1.  Unresolved issues and current concepts in management of primary glomerulonephritis.

Authors:  Suresh Chandra Dash; Fahd A Al-Muhanna
Journal:  Ann Saudi Med       Date:  2005 Jul-Aug       Impact factor: 1.526

2.  Renal Survival in Children with Glomerulonephritis with Crescents: A Pediatric Nephrology Research Consortium Cohort Study.

Authors:  Joseph G Maliakkal; M John Hicks; Mini Michael; David T Selewski; Katherine Twombley; Michelle N Rheault; Meredith Seamon; Jason M Misurac; Cheryl L Tran; Loretta Reyes; Joseph T Flynn; Ali M Onder; Alexandru R Constantinescu; Vaishali Singh; Cynthia Pan; Abiodun Omoloja; Qiang Wu; William E Smoyer; Guillermo Hidalgo; Scott E Wenderfer
Journal:  J Clin Med       Date:  2020-07-26       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.